Welcome to our dedicated page for AQUA news (Ticker: AQUA), a resource for investors and traders seeking the latest updates and insights on AQUA stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect AQUA's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of AQUA's position in the market.
Evoqua Water Technologies (NYSE: AQUA) has appointed Julia (Julie) Sloat as an independent director and member of the Audit Committee. With extensive experience in corporate finance and utility operations, Sloat is expected to contribute valuable insights for the company's growth. She is currently the CFO at American Electric Power and has held various leadership roles in both finance and operations. Evoqua, headquartered in Pittsburgh, specializes in water and wastewater treatment solutions, serving over 38,000 customers globally.
Evoqua Water Technologies (NYSE: AQUA) announced its participation in six investor events during February and March 2022. Key appearances include a fireside chat by Ben Stas at the Citi Global Industrials Conference on February 22 at 12:10 p.m. ET, and Snehal Desai's chat at the Baird Sustainability Conference on February 23 at 1:10 p.m. ET. Other conferences include the JP Morgan High Yield Conference, Berenberg Industrial Technologies Conference, Raymond James Institutional Investors Conference, and NYSE Energy & Utilities Virtual Investor Access Day. Evoqua provides critical water treatment solutions globally.
Evoqua Water Technologies (NYSE:AQUA) reported its first quarter 2022 results, achieving $366.3 million in revenue, a 13.7% increase year-over-year. Organic revenue rose 13.0%, driven by higher product and service volumes. However, net income decreased 6.2% to $6.1 million, impacted by rising operating expenses. Adjusted EBITDA climbed 21.2% to $54.3 million. The company raised fiscal year 2022 revenue guidance to $1.62 to $1.70 billion and adjusted EBITDA to $280 to $300 million. Evoqua's acquisition of Mar Cor aims to enhance growth in the Life Sciences market.
Evoqua Water Technologies (NYSE: AQUA) has achieved a significant milestone by being ranked 19th on the 2022 Global 100 Most Sustainable Corporations list, an accolade announced on January 19, 2022. This is Evoqua's first entry into this prestigious ranking, recognizing its dedication to sustainability within the water treatment sector. The Global 100 is a ranking of the top one percent of public companies for sustainability performance, evaluated based on metrics such as Clean Revenue and Clean Investment.
Evoqua Water Technologies Corp. (NYSE: AQUA) will hold its First Quarter earnings conference call on February 1, 2022, at 10:00 a.m. ET. A press release with the Company's earnings results will be issued prior to the call. For participation, US dial-in is (800) 909-5202 and international is (785) 424-1250. A replay of the call will be available from 1:00 p.m. ET on February 1 until 11:59 p.m. on February 15. The webcast and presentation slides will be accessible on Evoqua's Investor Relations website.
Evoqua Water Technologies (NYSE: AQUA) has completed the acquisition of the renal business from STERIS Plc (NYSE: STE), previously operated by Mar Cor Purification and Cantel Medical. The acquisition is projected to bring in approximately $180 million in annual revenues and an adjusted EBITDA of around $27 million before synergies. This strategic move is set to enhance Evoqua's presence in the healthcare market across North America, leveraging Mar Cor's expertise in high-purity water treatment systems across 5,500 sites.
Evoqua Water Technologies (NYSE: AQUA) announced an agreement to acquire the renal business assets of Mar Cor Purification and Cantel Medical, subsidiaries of STERIS Plc (NYSE: STE), for $196.3 million. This acquisition aims to enhance Evoqua's medical water purification solutions and expand its footprint in the healthcare market. The transaction, expected to close in Q2 FY2022, is projected to generate annual revenues of approximately $180 million and adjusted EBITDA of around $27 million prior to synergies.
FAQ